Dendritic cells are a specialised group of white blood cells that function as an on and off switch for the defence mechanism. This means that dendritic cells are ideally suited to regulating the defence response. With antiviral or antitumor vaccination, it is important that the dendritic cells activate the defence mechanism properly. With autoimmune diseases such as multiple sclerosis, the defence mechanism has to be correctly suppressed. In order to stifle unwanted defence reactions on a specific basis with autoimmune diseases, allergies and symptoms of rejection following transplants, vaccination with immunosuppressant or tolerogenic dendritic cells could offer a possible solution. Thanks to the financial support of the Charcot research fund, we are to investigate whether we can modify the function of dendritic cells by switching off certain transcriptional processes in the cell so that the autoimmune reaction targeting pituitary antigens in multiple sclerosis are stifled. This should enable us to evaluate the feasibility and applicability of a cellular vaccine for the treatment of multiple sclerosis preclinically.